Role of proteolysis in development of murine adipose tissue

Summary

Obesity is a common disorder, and related diseases such as diabetes, atherosclerosis, hypertension, cardiovascular disease and cancer are a major cause of mortality and morbidity inWesterntype societies. Development of obesity is associated with extensive modifications in adipose tissue involving adipogenesis, angiogenesis and extracellular matrix proteolysis. The fibrinolytic (plasminogen/plasmin) and matrix metalloproteinase (MMP) systems cooperate in these processes. A nutritionally induced obesity model in transgenic mice has been used extensively to study the role of the fibrinolytic and MMP systems in the development of obesity. These studies support a role of both systems in adipogenesis and obesity, and suggest that modulation of proteolytic activity may affect development of adipose tissue.

Keywords

Animal models - fibrinolysis inhibitors - gene knock-out - matrix metalloproteinases - obesity

• References

• 1 Hedley AA, Ogden CL, Johnson CL. et al. Prevalence of overweight and obesity among US children, adolescents, and adults 1999-2000. J Am Med Assoc 2004; 291: 2847-2850.
• 2 Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
• 3 Roth J, Qiang X, Marban SL. et al. The obesity pandemic: where have we been and where are we going?. Obes Res 2004; 12 (Suppl. 02) 88S-101S.
• 4 Nakajima I, Yamagushi T, Ozutsumi K. et al. Adipose tissue ECM: newly organized by adipocytes during differentiation. Differentiation 1998; 63: 193-200.
• 5 Lijnen HR, Maquoi E, Holvoet P. et al. Adipose tissue expression of gelatinases in mouse models of obesity. Thromb Haemost 2001; 85: 1111-1116.
• 6 Crandall DL, Hausman EJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic and angiogenic perspectives. Microcirculation 1997; 4: 211-232.
• 7 Lijnen HR, Collen D. Molecular and celluar basis of fibrinolysis. Hematology: basic principles and practice.. 4th ed. Philadelphia: Elsevier; 2005: 1955-1959.
• 8 Morange PE, Bastelica D, Bonzi MF. et al. Influence of t-PA and u-PA on adipose tissue development in a murine model of diet-induced obesity. Thromb Haemost 2002; 87: 306-310.
• 9 Miskin R, Masos T. Transgenic mice overexpressing urokinase-type plasminogen activator in the brain exhibit reduced food consumption body weight and size, and increased longevity. J Gerontol 1997; 52A: B118-24.
• 10 Hoover-Plow J, Ellis J, Yuen L. In vivo plasminogen deficiency reduces fat accumulation. Thromb Haemost 2002; 87: 1011-1019.
• 11 Lijnen HR. Deficiency of α2-antiplasmin does not affect murine adipose tissue development. Thromb Haemost 2007; 5: 420-421.
• 12 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568-582.
• 13 Shimomura I, Funahashi T, Takahashi M. et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
• 14 Alessi MC, Peiretti F, Morange P. et al. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
• 15 Alessi MC, Bastelica D, Morange P. et al. Plasminogen activator inhibitor-1, transforming growth factor-beta 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-1380.
• 16 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
• 17 Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995; 92: 1779-1785.
• 18 Mavri A, Stegnar M, Krebs M. et al. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 19: 1582-1587.
• 19 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.
• 20 Morange PE, Lijnen HR, Alessi MC. et al. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000; 20: 1150-1154.
• 21 Lijnen HR, Maquoi E, Morange PE. et al. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
• 22 Eren M, Su M, Atkinson J. et al. Phenotypic derangements associated with overexpression of plasminogen activator inhibitor-1 in transgenic mice. Arterioscler Thromb Vasc Biol 2001; 21: 695. (Abstract 230).
• 23 Schäfer K, Fujisawa K, Konstantinides S. et al. Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-1842.
• 24 Ma LF, Mao SL, Taylor KL. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor-1. Diabetes 2004; 53: 336-346.
• 25 Sierra-Honigman MR, Nath AK, Murakami C. et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683-1686.
• 26 Lijnen HR. Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Thromb Haemost 2005; 93: 816-819.
• 27 Scroyen I, Christiaens V, Lijnen HR. No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation. Thromb Haemost 2006; 4: 1-7.
• 28 Liang X, Kanjanabuch T, Mao SL. et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 2006; 290: E103-E113.
• 29 Lijnen HR, Frederix L, Scroyen I. Deficiency of plasminogen activator inhibitor-2 impairs nutritionally induced murine adipose tissue development. J Thromb Haemost 2007; 5: 2259-2265.
• 30 Lijnen HR, Alessi MC, Frederix L. et al. Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost 2006; 96: 731-737.
• 31 Crandall DL, Quinet EM, El Ayachi S. et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006; 26: 2209-2215.
• 32 Gomez DE, Alonso DF, Yoshiji H. et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
• 33 Brown LM, Fox HL, Hazen SA. et al. Role of the matrixin MMP-2 in multicellular organization of adipocytes cultured in basement membrane components. Am J Physiol 1997; 272: C937-949.
• 34 Bouloumié A, Sengenès C, Portolan G. et al. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001; 50: 2080-2086.
• 35 Johnson MD, Kim HR, Chesler L. et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160: 194-202.
• 36 Maquoi E, Munaut C, Colige A. et al. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002; 51: 1093-1101.
• 37 Maquoi E, Demeulemeester D, Voros G. et al. Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation. Thromb Haemost 2003; 89: 696-704.
• 38 Alexander CM, Selvarajan S, Mudgett J. et al. Stromelysin-1 regulates adipogenesis during mammary gland involution. J Cell Biol 2001; 152: 693-703.
• 39 Lijnen HR, Van Hoef B, Frederic L. et al. Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity. Thromb Haemost 2002; 87: 530-535.
• 40 Lijnen HR, Demeulemeester D, Van Hoef B. et al. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb Haemost 2003; 89: 249-255.
• 41 Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
• 42 Demeulemeester D, Scroyen I, Voros G. et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development. Thromb Haemost 2006; 95: 1019-1024.
• 43 Lijnen HR, Maquoi E, Hansen LB. et al. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol 2002; 22: 374-379.
• 44 Demeulemeester D, Collen D, Lijnen HR. Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Comm 2005; 329: 105-110.
• 45 Rupnick MA, Panigrahy D, Zhang CY. et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002; 99: 10730-10735.
• 46 Bourlier V, Zakaroff-Girard A, De Barros S. et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther 2005; 312: 1272-1279.
• 47 Wolfsberg TG, Straight PD, Gerena RL. et al. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev Biol 1995; 169: 378-383.
• 48 Kaushal GP, Shah SB. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinase of the ADAM family. J Clin Invest 2000; 105: 1335-1337.
• 49 Voros G, Maquoi E, Collen D. et al. Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-α, TNF-α converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta 2003; 1625: 36-42.
• 50 Voros G, Sandy JD, Collen D. et al. Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development. Biochim Biophys Acta 2006; 1760: 1837-1844.